A Phase 2 interventional study of Met DR and Met XR in Renal Insufficiency, sponsored by Elcelyx Therapeutics, Inc.. Completed. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-12-30.
Sponsored by Elcelyx Therapeutics, Inc. · Phase 2, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study evaluated how a single dose of delayed-release metformin (Met DR) behaves in subjects with normal kidney function, mild kidney dysfunction, moderate kidney dysfunction, or severe kidney dysfunction. The safety and tolerability of Met DR was also examined. In addition, this study compared the behavior of a single dose of Met DR with that of extended-release metformin (Met XR) and placebo in subjects with the varying levels of kidney function described above.
1,414 studies on the registry are indexed under Renal Insufficiency; 147 are open to participants now.
This study's enrollment of 39 is close to the median of 40 across 1,062 interventional studies indexed under Renal Insufficiency.
Browse Renal Insufficiency studies →Elcelyx Therapeutics, Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male, or female and met all of the following criteria:
Exclusion Criteria:
Had a medical condition that could potentially affect study participation and/or personal well-being, as judged by the investigator, including but not limited to the following conditions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One dose of 1000 mg metformin delayed-release
Drug: Met DR
One dose of 1000 mg metformin extended-release
Drug: Met XR
One dose of Placebo
Drug: Placebo
AUC (0-t) of Plasma Metformin
AUC (0-t) = Area under the curve from the time of dosing (0 h) to the time of the last quantifiable concentration following dose administration
Time frame: from the time of dosing (0 h) to 72 hours postdose
Cmax of Plasma Metformin
Cmax = Maximum concentration from the time of dosing (0 h) to the time of the last quantifiable metformin concentration following dose administration
Time frame: from the time of dosing (0 h) to 72 hours postdose
Correlation of Placebo-adjusted Change From Pre-dose Value in Lactate Versus Metformin Concentration
To determine the exposure-response relationship of metformin and plasma lactate concentrations
Time frame: from the time of dosing (0 h) to 24 hours postdose
| Milestone | Sequence ABC | Sequence CAB | Sequence BCA |
|---|---|---|---|
| Started | 14 | 11 | 14 |
| Completed treatment a | 14 | 11 | 12 |
| Completed treatment b | 13 | 11 | 14 |
| Completed treatment c | 13 | 11 | 12 |
| Started - normal rf cohort only | 3 | 2 | 3 |
| Completed - normal rf cohort only | 3 | 2 | 3 |
| Started - mild ri cohort only | 4 | 3 | 4 |
| Completed - mild ri cohort only | 4 | 3 | 4 |
| Started - moderate ri cohort only | 4 | 4 | 4 |
| Completed - moderate ri cohort only | 3 | 4 | 2 |
| Started - severe ri cohort only | 3 | 2 | 3 |
| Completed - severe ri cohort only | 3 | 2 | 3 |
| Completed | 13 | 11 | 12 |
| Not completed | 1 | 0 | 2 |
| Withdrew: Protocol violation | 1 | 0 | 2 |
AUC (0-t) = Area under the curve from the time of dosing (0 h) to the time of the last quantifiable concentration following dose administration
| ng*h/mL | Met DR | Met XR |
|---|---|---|
| Normal (N = 8) | 5362 ± 943 | 10411 ± 1831 |
| Mild RI (N = 10) | 8705 ± 1368 | 11788 ± 1853 |
| Moderate RI (N = 9) | 11477 ± 1915 | 20240 ± 3377 |
| Severe RI (N = 7) | 22893 ± 4307 | 43683 ± 8218 |
Cmax = Maximum concentration from the time of dosing (0 h) to the time of the last quantifiable metformin concentration following dose administration
| ng/mL | Met DR | Met XR |
|---|---|---|
| Normal (N = 8) | 969 ± 153 | 1479 ± 234 |
| Mild RI (N = 10) | 1036 ± 147 | 1340 ± 189 |
| Moderate RI (N = 9) | 925 ± 139 | 1634 ± 245 |
| Severe RI (N = 7) | 1414 ± 239 | 2590 ± 438 |
To determine the exposure-response relationship of metformin and plasma lactate concentrations
| R² | Met DR | Met XR |
|---|---|---|
| Correlation of Placebo-adjusted Change From Pre-dose Value in Lactate Versus Metformin Concentration | 0.000011129 | 0.069527 |
Collected over Approximately 19 to 76 days depending on the number of days before the start of Visits 2 and 3 and the number of washout days between the treatment visits.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/36 (0%) | 4/36 (11.1%) |
| Met DR | — | 0/38 (0%) | 12/38 (31.6%) |
| Met XR | — | 0/37 (0%) | 11/37 (29.7%) |
| Event | Placebo | Met DR | Met XR |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/36 | 3/38 | 4/37 |
| DizzinessNervous system disorders | 0/36 | 0/38 | 2/37 |
| Vessel Puncture Site HaemorrhageGeneral disorders | 0/36 | 2/38 | 1/37 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/36 | 2/38 | 1/37 |
| DyspepsiaGastrointestinal disorders | 1/36 | 1/38 | 1/37 |
| ConstipationGastrointestinal disorders | 1/36 | 0/38 | 0/37 |
| Food PoisoningGastrointestinal disorders | 1/36 | 0/38 | 0/37 |
| HypoglycaemiaMetabolism and nutrition disorders | 1/36 | 0/38 | 0/37 |
| Blood Creatine Phosphokinase IncreasedInvestigations | 1/36 | 0/38 | 0/37 |
| NauseaGastrointestinal disorders | 0/36 | 1/38 | 1/37 |
Randomized Population - All subjects were to receive all interventions and are distributed in this module according to their renal function cohort to inform PK analyses comparing these populations
| Age, Continuous(years) | Normal | Mild RI | Moderate RI | Severe RI | Total |
|---|---|---|---|---|---|
| Mean | 54.5 ± 11.01 | 60.8 ± 6.62 | 72.6 ± 3.90 | 70.5 ± 5.50 | 65.1 ± 9.83 |
| Sex: Female, Male(Participants) | Normal | Mild RI | Moderate RI | Severe RI | Total |
|---|---|---|---|---|---|
| Female | 2 | 4 | 0 | 1 | 7 |
| Male | 6 | 7 | 12 | 7 | 32 |
| Ethnicity (NIH/OMB)(Participants) | Normal | Mild RI | Moderate RI | Severe RI | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 2 | 0 | 3 |
| Not Hispanic or Latino | 8 | 10 | 10 | 8 | 36 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Normal | Mild RI | Moderate RI | Severe RI | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 1 | 1 |
| Black or African American | 1 | 5 | 2 | 4 | 12 |
| White | 7 | 6 | 10 | 3 | 26 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Body Weight(kg) | Normal | Mild RI | Moderate RI | Severe RI | Total |
|---|---|---|---|---|---|
| Mean | 94.9 ± 18.02 | 94.9 ± 12.06 | 94.2 ± 14.96 | 99.8 ± 10.69 | 95.7 ± 13.73 |
| BMI(kg/m²) | Normal | Mild RI | Moderate RI | Severe RI | Total |
|---|---|---|---|---|---|
| Mean | 32.8 ± 3.81 | 31.8 ± 3.79 | 30.4 ± 3.33 | 33.3 ± 4.09 | 31.9 ± 3.75 |
No study locations are listed for this record.
The record gives a start of Jan 2014, a primary completion of Jun 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2015, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Metformin
Elcelyx Therapeutics, Inc.